Home Cart Sign in  
Chemical Structure| 118876-58-7 Chemical Structure| 118876-58-7

Structure of NBQX
CAS No.: 118876-58-7

Chemical Structure| 118876-58-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NBQX is a potent, selective and competitive AMPAR antagonist, which shows activity of neuroprotective and anticonvulsant.

Synonyms: FG9202; NNC 079202

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NBQX

CAS No. :118876-58-7
Formula : C12H8N4O6S
M.W : 336.28
SMILES Code : O=S(C1=C2C(C3=C(NC(C(N3)=O)=O)C=C2[N+]([O-])=O)=CC=C1)(N)=O
Synonyms :
FG9202; NNC 079202
MDL No. :MFCD00270054
InChI Key :UQNAFPHGVPVTAL-UHFFFAOYSA-N
Pubchem ID :3272524

Safety of NBQX

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 50 µM 4 hours Competitive inhibition of CAM2(TCO) labeling to AMPARs Nat Commun. 2021 Feb 5;12(1):831
Primary cortical neurons 50 µM 10 hours Competitive inhibition of CAM2(TCO) labeling to endogenous AMPARs Nat Commun. 2021 Feb 5;12(1):831
Hippocampal slice culture neurons 10 µM 14 days To record NMDAR-mediated excitatory postsynaptic currents (NMDAR EPSCs), results showed complete elimination of NMDAR EPSCs in CRISPR/Cas9 transfected cells. Neuron. 2014 Sep 3;83(5):1051-7
Human primary osteoblasts (HOBs) 200 µM 20 days To evaluate the effects of NBQX on the number and mineralization of human primary osteoblasts. NBQX treatment reduced cell number and prevented mineralization. Ann Rheum Dis. 2015 Jan;74(1):242-51

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice AMPA- or NMDA-induced lethal convulsions model Intraperitoneal injection 18.0 mg/kg (NMDA), 17.0 mg/kg (AMPA) Single dose, observed 5 minutes after administration Evaluate the protective effect of NBQX against AMPA- or NMDA-induced lethal convulsions Br J Pharmacol. 1998 Nov;125(6):1258-66
Lewis rats Antigen-induced arthritis (AIA) model Intra-articular injection 2.5 mM Single injection, observed for 21 days To evaluate the effects of NBQX on joint swelling, inflammation, and degeneration in the AIA rat model. NBQX significantly reduced joint swelling (33%), inflammation scores (34%), and degeneration scores (27%). Ann Rheum Dis. 2015 Jan;74(1):242-51
Long-Evans rats Hypoxia-induced neonatal seizure model Intraperitoneal injection 20 mg/kg Every 12 hours for 4 doses NBQX treatment significantly attenuated seizure-induced increases in p-P70S6K in the hippocampus and cortex, reduced the frequency of spontaneous recurrent seizures in adulthood, decreased aberrant mossy fiber sprouting in the CA3 region of the hippocampus, and restored preference for social novelty. Epilepsia. 2013 Nov;54(11):1922-32
Rats 3NP-induced striatal neurodegeneration Subcutaneous injection 24 mg/kg/day Continuous for 28 days NBQX attenuated the toxicity of 3NP, reducing the loss of striatal neurons Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12885-90
Mice Maximal electroshock seizures (MES) and pentylenetetrazol (PTZ)-induced seizure models Intraperitoneal injection 80-120 mg/kg Single administration, threshold determined 15 minutes later NBQX significantly increased the threshold for electroshock and PTZ-induced seizures, but only at doses causing sedation and ataxia. Br J Pharmacol. 1994 Dec;113(4):1349-57
C57BL/6J mice TMEV-induced seizure model Intraperitoneal injection approximately 22.5 mg/kg twice daily Twice daily, from day 2.5 to day 10.5 post infection NBQX treatment significantly increased the number of mice experiencing seizures, the number of seizures per mouse, the cumulative seizure score per mouse, and the mortality rate. Exp Neurol. 2016 Jun;280:89-96

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.97mL

0.59mL

0.30mL

14.87mL

2.97mL

1.49mL

29.74mL

5.95mL

2.97mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories